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Background: Tramadol is a centrally acting analgesic prescribed off-label for the treatment of premature ejaculation
(PE). However, tramadol may cause addiction and difficulty in breathing and the beneficial effect of tramadol in PE is
yet not supported by a high level of evidence. The purpose of this study was to systematically review the evidence
from randomised controlled trials (RCT) for tramadol in the management of PE.
Methods: We searched bibliographic databases including MEDLINE to August 2014 for RCTs. The primary outcome
was intra-vaginal ejaculatory latency time (IELT). Methodological quality of RCTs was assessed. Between-group
differences in IELT and other outcomes were pooled across RCTs in a meta-analysis. Statistical and clinical between-trial
heterogeneity was assessed.
Results: A total of eight RCTs that evaluated tramadol against a comparator were included. The majority of RCTs were of
unclear methodological quality due to limited reporting. Pooled evidence (four RCTs, 721 participants), suggests that
tramadol is significantly more effective than placebo at increasing IELT over eight to 12 weeks (p = 0.0007). However, a
high level of statistical heterogeneity is evident (I-squared = 74%). Single RCT evidence indicates that tramadol is
significantly more effective than paroxetine taken on-demand, sildenafil, lidocaine gel, or behavioural therapy on IELT in
men with PE. Tramadol is associated with significantly more adverse events including: erectile dysfunction, constipation,
nausea, headache, somnolence, dry mouth, dizziness, pruritus, and vomiting, than placebo or behavioural therapy over
eight to 12 weeks of treatment. However, addiction problems or breathing difficulties reported by patients for PE is not
assessed in the current evidence base.
Conclusions: Tramadol appears effective in the treatment of PE. However, these findings should be interpreted with
caution given the observed levels of between-trial heterogeneity and the reporting quality of the available evidence.
The variability across placebo-controlled trials in terms of the tramadol dose evaluated and the treatment duration does
not permit any assessment of a safe and effective minimum daily dose. The long-term effects and side effects, including
addiction potential, for men with PE have not been evaluated in the current evidence base.
Trial registration: The review is registered on PROSPERO 2013:CRD42013005289.
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Premature ejaculation (PE) is commonly defined by a
short ejaculatory latency, a perceived lack of ejaculatory
control; both related to self-efficacy; and distress and
interpersonal difficulty [1]. PE can be either lifelong
(primary), present since first sexual experiences, or* Correspondence: m.martyn-stjames@sheffield.ac.uk
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article, unless otherwise stated.acquired (secondary), beginning later [2]. The recently
updated International Society of Sexual Medicine’s
Guidelines for the Diagnosis and Treatment of Prema-
ture Ejaculation (PE) propose that PE is a male sexual
dysfunction characterised by ejaculation within about
one minute of vaginal penetration (lifelong PE) or a re-
duction in latency time to ≤3 minutes (secondary PE),
the inability to delay ejaculation, and negative personal
consequences [3].d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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concern about the condition as well as increase sexual
satisfaction for the patient and the partner [4]. Available
treatment pathways for the condition are varied and
treatments may include both behavioural and/or phar-
macological interventions. Tramadol is a centrally
acting analgesic agent that combines opioid receptor
activation and re-uptake inhibition of serotonin and
noradrenaline, prescribed off-label for the treatment of
PE. Dapoxetine (a selective serotonin re-uptake inhibitor)
is currently the only approved oral drug to treat PE. In
May 2009, the US Food and Drug Administration re-
leased a warning letter about tramadol's potential to
cause addiction and difficulty in breathing [5]. Tramadol
has previously been evaluated by three systematic re-
views [6-8], two of which have pooled data in a meta-
analysis [7,8]. The search methodology and inclusion
criteria vary across these reviews. Of the two reviews in-
cluding a meta-analysis, one [7] pooled data across dif-
ferent study types (observational studies and RCTs)
using a mean difference [7]. One review pooled IELT ef-
fect estimates across studies using a standardised mean
difference [8]. The European Association of Urology
guidelines for the management of PE summarise that
tramadol has shown a moderate beneficial effect with a
similar efficacy as dapoxetine. However, that the benefi-
cial effect of tramadol in PE is yet not supported by a
high level of evidence [9].
The aim of this study was to systematically review the
evidence base for tramadol in the management of PE,
by summarising evidence from randomised controlled
trials (RCTs) and reporting a mean difference meta-
analysis of RCT IELT data. The review addressed the
question “in men with premature ejaculation, what is
the clinical effectiveness of tramadol as compared
with a non-active comparators or other treatments,
evaluated in randomised controlled trials”. The review




The review was undertaken in accordance with the ge-
neral principles recommended in the Preferred Repor-
ting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [10].
Searches
The following databases were searched from inception
to 5 August 2014 for published and unpublished re-
search evidence: MEDLINE; Embase; Cumulative Index
to Nursing and Allied Health Literature (CINAHL); The
Cochrane Library including the Cochrane Systematic
Reviews Database (CDSR), Cochrane Controlled TrialsRegister (CCRT), Database of Abstracts of Reviews of
Effects (DARE) and the Health Technology Assessment
(HTA) database; ISI Web of Science (WoS), including
Science Citation Index, and the Conference Proceedings
Citation Index-Science. Full search terms are reported
elsewhere [11]. The U.S. Food and Drug Administration
(FDA) website and the European Medicines Agency
(EMA) website were also searched. Existing systematic
reviews were also checked for eligible studies. All
citations were imported into Reference Manager Soft-
ware and any duplicates deleted. The MEDLINE search
strategy is presented as an Additional file 1.
Study selection
Searches were screened for potentially relevant studies
by one reviewer and a subset checked by a second re-
viewer (and a check for consistency undertaken). Full
texts were screened by two reviewers. Details of studies
identified for inclusion were extracted using a data ex-
traction sheet.
Eligible studies
RCTs in adult men with PE that evaluated tramadol
were eligible for inclusion. Randomised crossover de-
sign studies were excluded to avoid double counting of
participants in the meta-analysis. Theses and disserta-
tions were not included. Non-English publications were
included where sufficient data could be extracted from
an English-language abstract or tables.
Outcomes
The primary outcome was intra-vaginal ejaculatory
latency time (IELT). Other outcomes included sexual
satisfaction, control over ejaculation, relationship satis-
faction, self-esteem, quality of life, treatment accept-
ability and adverse events.
Data extraction
One reviewer performed data extraction of each in-
cluded study. All numerical data were then checked by a
second reviewer.
Methodological quality of studies
Methodological quality of RCTs was assessed using the
Cochrane Collaboration risk of bias assessment criteria
[12]. We classified RCTs as being at overall ‘low’ or
‘high’ risk of bias if they were rated as such for each of
three key domains - allocation concealment, blinding of
outcome assessment and completeness of outcome data
(attrition <30%).
Data synthesis
Where possible, between-group differences for direct
comparisons (e.g., tramadol vs. placebo) were pooled
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RevMan software (version 5.2) (RevMan 2012 [13]).
Continous variables were analysed as a mean difference
(MD) and dichotomous variables as a risk ratio (RR).
No subgroup or sensitivity analyses were planned. For
comparisons where there was little apparent clinical
heterogeneity and the I2 value (I2 statistic [14]) was 40%
or less, a fixed-effect model was applied. Random-
effects models were applied where I2 value was >40%.
Between-group effect estimates were considered sig-
nificant at p < 0.05. Where >5 RCT comparisons were
available, publication bias was assessed by visual in-
spection of funnel plots.Ethical approval and consent from patients
The project was not primary research involving humans
or animals but was a secondary analysis of human sub-

































Full text articles assessed
8 RCTs included in the evidence s
Figure 1 Study selection process - Preferred Reporting Items for SystResults
Search results
The searches identified 2,331 citations (as part of a wider
project assessing a variety of treatments for PE [11]). Of
these, 2,319 citations were excluded as titles/abstracts.
Twelve full-text articles were obtained as potentially
relevant. The study selection process is fully detailed in
the PRISMA flow diagram in Figure 1. A total of seven
RCTs that evaluated tramadol against a comparator
(placebo, another agent, or behavioural therapy) and one
RCT that evaluated different tramadol doses (eight RCTs
in total) were identified.
Details of the included RCTs, the comparator(s),
outcomes assessed and the risk of bias assessment are
detailed in Table 1.
Risk of bias assessment of RCTs
The majority of RCTs were considered at overall unclear







Full text articles excluded, with
reasons (n=4):
Review of SRRIs (n=3)
Crossover tramadol trials (n=1)
ynthesis
ematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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- Tramadol 50 mg 2 to 3 h PC, 17/17
(100%) - Paroxetine 20 mg/d, 18/18
(100%)
IELT (Stopwatch): see Figure 3. Arabic Index
of Premature Ejaculation (AIPE): significant
improvement in scores at 6 weeks with both
tramadol and paroxetine. Difference between
groups not significant. Tramadol group had
less rigid erections than paroxetine group
The drugs were generally tolerated
and no serious side-effects encountered
apart from mild headache and gastric
upset with paroxetine and mainly gastric
upset with tramadol and no withdrawn
cases recorded.












- Tramadol 62 mg, 206/232 (89%) -
Tramadol 89 mg, 198/217 (91%) -
Placebo, 200/228 (88%) 2 to 8 h PC
IELT (Stopwatch): see Figure 3. Premature
Ejaculation Profile (PEP): Mean change for all
4 measures significantly higher in both
tramadol groups than placebo Female
partner PEP scores: more had improvement
(> = 1 category) for tramadol than placebo
on all 4 measures
Any adverse event: Tramadol 62
mg: 12% Tramadol 89 mg: 16% Placebo:
7% No difference was observed in the
incidence of withdrawal by treatment
group (0.0% placebo, 1.0% 62 mg
tramadol, 1.6% 89 mg tramadol). There
were no serious AEs.







PE def, NR All
lifelong PE
ED, excluded
- Tramadol 25 mg, 100/100 (100%) -
Tramadol 50 mg, 100/100 (100%) -
Tramadol 100 mg, 100/100 (100%)
2 to 3 h PC
IELT (Stopwatch): see Figure 3 Tramadol 25 mg - somnolence (100%);
pruritus (100%) Tramadol 50 mg -
somnolence (100%); pruritus (100%);
dizziness (18%); headache (16%); dry
mouth (13%) Tramadol 100 mg -
somnolence (100%); pruritus (100%);
dizziness (38%); headache (30%); dry
mouth (20%); nausea (20%); vomiting
(17%)








IELT of <2 min
in >75% of
episodes All had
PE for >1 year
ED, excluded
- Tramadol 50 mg 2 h PC + inert
lubricating gel 15 min PC, 29/30 (97%) -
Sildenafil 50 mg 1 h PC + inert lubricating
gel 15 min PC, 30/30 (100%) - Paroxetine
20 mg 4 h PC + inert lubricating gel
15 min PC, 28/30 (93%) - Lidocaine gel
15 min PC + oral multivitamin 1-4 h PC,
30/30 (100%) - Placebo (oral multivitamin
1-4 h PC + inert lubricating gel 15 min
PC), 27/30 (90%)
IELT (stopwatch): see Figure 3. Sexual
satisfaction (0 to 5 point scale: Tramadol and
paroxetine were associated with comparable
drug-induced improvements in sexual
satisfaction, but tramadol was associated with
significantly better sexual satisfaction scores
than was the local anaesthetic.
Greater sleep disturbance, dry mouth,
nausea, dizziness, fatigue, vomiting,
sweating, and headache were reported
with tramadol, sildenafil and paroxetine.
All side effects were reported as being
tolerable.











- Tramadol 100 mg/d, 4 weeks then 2 or
8 h PC, 4 weeks; 30/30 (100%) - Placebo/
d, 4 weeks then 2 or 8 h PC, 4 weeks;
30/30 (100%)
IELT (stopwatch): Week 8 tramadol daily 202.5 s,
2 or 8 h PC, 238.2 s (p < 0.001 vs baseline);
placebo daily 94.8 s (p = 0.632 vs baseline)
placebo 2 or 8 h PC 96.6 s (p = 0.611 vs
baseline). Coital frequency tramadol daily
4.32/week (p = 0.005) tramadol 2 or 8 h PC
4.86/week (p = 0.005). Coital frequency placebo
daily 2.88/week (p = 0.875) placebo 2 or 8 h
PC 3.23/week (p = 0.752).
The overall AE rate was 9.8% (6.7%, and
12.4% for placebo and 100 mg tramadol
respectively) ED occurred in 3.33% of
men (n = 1). Vertigo was observed in
3.33% of patients (n = 2); dizziness,
headache, drowsiness, and common
cold were observed in 6.67% of patients
(n = 2 each). There were no serious AEs.



































- Tramadol 25 mg, 30/30 (100%) -
Placebo, 30/30 (100%) 2 h PC
IELT (stopwatch): see Figure 3. Ability of
ejaculation control (AEC): Tramadol: Mean
increase 2.0 Placebo: Mean increase 0.57
Tramadol better than placebo (p < 0.001)
Sexual satisfaction scores (SSS) Tramadol:
Mean increase 1.80 (SD 0.98). Placebo: Mean
increase 0.53 (SD 0.92) Tramadol better than
placebo (p < 0.001)
Any adverse event: Tramadol: 27%
Placebo: 0% Mild nausea/headache:
Tramadol: 20% Mild somnolence:
Tramadol: (6.5%)












- Tramadol 50 mg, 29/32 (91%) -
Placebo, 28/32 (88%) 2 h PC
IELT (stopwatch): see Figure 3. IIEF: intercourse
satisfaction: Tramadol: mean change 4 Placebo:
mean change −1 Between-groups p < 0.05
Any adverse event: Tramadol: 28%
Placebo: 16% (mainly nausea)






IELT ≤2 min All
lifelong PE ED, NR
- Tramadol 50 mg 2 h PC with behavioural
therapy (not reported which) (n = 36) -
Behavioural therapy alone (n = 36);
IELT (stopwatch): see Figure 3. IIEF Tramadol +
BT: mean change 4 BT alone: mean change 2
Between-groups p < 0.05
Any adverse event: Tramadol: 28%
Placebo: 0% Tramadol: nausea (11.1%),
vomiting (2.8%), dry mouth (5.6%),
dizziness (8.3%).
Unclear risk - allocation
method and blinded
outcome assessment not
reported (unable to assess
fully – body text of article
in Chinese)
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described as single-blind and were considered at high risk
of performance bias [15-17]. One RCT was considered to
be at overall high risk of bias as randomisation to study
groups was according to patients’ presentation sequence
at clinic, suggesting a non-random component in the se-
quence generation [17]. A summary of the risk of bias as-
sessment for each included RCT is presented in Figure 2.
Characteristics of RCTs
RCT details of the treatments, efficacy and safety out-
comes, and the risk of bias assessment are presented in
Table 1. Where reported, the definition of PE was varied
and was defined according to: DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders) criteria [15,18],
an IELT of two minutes or less [16,17,19], or was not re-
ported [20]. The majority of RCTs recruited samplesFigure 2 Risk of bias assessment summary by RCT.comprising men with lifelong PE and without erectile
dysfunction.
Tramadol was prescribed across all RCTs, on-demand
one to four hours prior to sexual intercourse. Prescribed
doses varied and range from 25 mg [17,20] to 100 mg
[20,21]. Comparators included placebo [17-19,21], se-
lective serotonin re-uptake inhibitors (SSRI) [15,16],
phosphodiesterase-5 (PDE5) inhibitors [16], anaesthetic
gel [16] and behavioural therapy [22]. One RCT evalu-
ated three tramadol doses only (no placebo) [20]. Treat-
ment duration ranged from four weeks to six months.
The majority of included RCTs were 8 weeks duration.
Only one trial was undertaken in the EU (across 11 EU
countries) [18]. The remainder were undertaken in
Egypt [15,16,20], Turkey [17], India [21], Iran [19] and
China [22].Outcome data reported by RCTs
IELT was assessed by all of the included RCTs (Table 1,
Figure 3, Figure 4). Where reported, the assessment
method was by stopwatch. The reporting of other efficacy
outcomes was much more varied, both in the assessment
method and the outcome data available (Table 1). Across
the majority of RCTs, outcome data for adverse event
reporting was disparate in terms of limited reporting of
types of adverse events and patient numbers.Data synthesis
IELT as a mean outcome with a variance estimate was
available for all but two RCTs [21,23]. One reported sig-
nificant changes in IELT at week eight in the tramadol
group (p < 0.001) [23]. P-values for the between-group
difference compared with placebo, or the change in the
placebo group, were not reported. One RCT reported
significant changes in IELT at week eight with tramadol
daily (p < 0.001) or on-demand (p < 0.001), but not pla-
cebo (p = 0.632 and 0.611). P-values for the between-
group difference were not reported.
Tramadol vs. placebo: Meta-analysis of mean IELT
change (minutes) at 8 or 12 week follow-up, based
on -four RCT study group comparisons from -three
RCTs (n = 721), displayed high heterogeneity (I2 = 74%).
The pooled mean difference (MD) in IELT was 1.24 mi-
nutes, favouring tramadol [MD (random effects) 95%
confidence interval [CI], 0.52 to 1.95; p = 0.009]. The
between-group difference in end of study values at four
weeks based on one RCT (n = 56) was 4.50 minutes (95%
CI 3.75 to 5.25; p < 0.00001), in favour of tramadol. The
forest plot for these analyses is presented in Figure 2.
Significant improvements on measures of the Premature
Ejaculation Profile (PEP) (p < 0.05 for all) with tramadol
compared with placebo were reported by one RCT [18]
Significant between-group differences on the International
Figure 3 Tramadol vs. comparator - forest plot of IELT outcomes.
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per week and mean intercourse satisfaction favouring
tramadol (p < 0.05) were reported by one RCT [19] A sta-
tistically significant increase in weekly coitus associated
with tramadol daily (p = 0.005) or on-demand (p = 0.005)
was reported by one RCT (p-values for placebo p = 0.875
and 0.752 respectively) [21]. One RCT reported significant
improvements on ability of ejaculation control and sexual
satisfaction scores (instrument not reported) for tramadol
over placebo (p < 0.001 for both) [17]. One RCT reported a
significant between-group difference of p < 0.05 on the IIEF
intercourse satisfaction score in favour of tramadol [17].
Where reported, adverse events associated with trama-
dol included: erectile dysfunction, constipation, nausea,headache, somnolence, dry mouth, dizziness, pruritus
(itching), and vomiting. Meta-analysis of numbers ex-
periencing adverse events at 8 or 12 week follow-up dis-
played low heterogeneity (I2 = 0%). The pooled relative
risk (RR) across five RCTs (583 participants) was 2.27
[RR (fixed effect) 95% confidence interval [CI], 1.45 to
3.57; p = 0.0004] in favour of placebo (lower risk). The
forest plot for this analysis is presented in Figure 4.
Tramadol vs. paroxetine (SSRI): The between-group
difference in geometric mean IELT (minutes) at 6 weeks,
based on one RCT (n = 70) comparing tramadol with
paroxetine taken daily, was −0.83 [95% CI, −1.80 to 0.14;
p = 0.09]. The between-group difference in end of study
mean IELT (minutes) at four weeks based on one RCT
Figure 4 Tramadol vs. comparator - forest plot for adverse events.
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favour of tramadol compared with paroxetine taken on-
demand (Figure 2).
One RCT [15] reported that paroxetine daily improved
the Arabic Index of Premature Ejaculation score at
6 weeks (p < 0.05) and 12 weeks (p < 0.05) whereas tram-
adol improved AIPE at 6 weeks but not at 12 weeks.
One RCT reported that both tramadol and paroxetine
on-demand were associated with comparable improve-
ments in sexual satisfaction (p > 0.05) [16].
One RCT reported that mild headache and gastric
upset were associated with paroxetine daily and mainly
gastric upset with tramadol [15] One RCT reported that
sleep disturbance, dry mouth, nausea, dizziness, fatigue,
vomiting, sweating, and headache were reported with
tramadol, sildenafil and paroxetine on-demand, but that
all side effects were tolerable [16].
Tramadol vs. sildenafil (PDE5 inhibitor): The between-
group difference in end of study mean IELT (minutes) at
four weeks based on one RCT (n = 59) was 2.01 (95% CI
1.21 to 2.87); p < 0.00001, in favour of tramadol (Figure 2).
Tramadol with behavioural therapy vs. behavioural
therapy alone: The between-group difference in mean
IELT (minutes) at 12 weeks, based on one RCT (n = 72),
was 1.65, significantly favouring tramadol combined with
behavioural therapy [95% CI, 0.30 to 3.00; p = 0.02]. The
forest plot for this analysis is presented in Figure 2. The
same RCT reported a between-group difference at
8 weeks of P < 0.05 on the International Index of Erectile
Function (IIEF) favouring the tramadol group [22]. The
between-group difference in numbers of participants ex-
periencing adverse events at 12 weeks was 21.00 [RR
(random effects) 95% confidence interval [CI], 1.28 to345.410; p = 0.03] in favour of behavioural therapy alone
(lower risk). The forest plot for this analysis is presented
in Figure 4.
Tramadol vs. lidocaine gel: The between-group diffe-
rence in end of study mean IELT (minutes) at four
weeks based on one RCT (n = 59) was 1.21 (95% CI 0.23
to 2.17); p = 0.02, in favour of tramadol (Figure 2). The
same RCT reported that tramadol was associated with
significantly better sexual satisfaction scores than was
the local anaesthetic (p < 0.05) [16].
Tramadol 25 mg, 50 mg, or 100 mg: One RCT (n = 300)
evaluated three different doses of tramadol. The between-
group differences in mean IELT (minutes) at 24 weeks
were: 10.65 in favour of tramadol 50 mg vs. 25 mg [95%
CI, 9.76 to 10.76; p < 0.00001]; 23.32 in favour of tramadol
100 mg vs. 25 mg [95% CI, 22.59 to 24.05; p < 0.00001];
and 13.06 in favour of tramadol 100 mg vs. 50 mg [95%
CI, 12.33 to 13.79; p < 0.00001]. The forest plot for this
analysis is presented in Figure 5. The same RCT [20], re-
ported that all patients in the trial experienced one or
more adverse events (all experienced somnolence and
pruritus).
Discussion
Pooled evidence across four RCT study groups (721 par-
ticipants), suggests that tramadol is significantly more
effective than placebo at increasing IELT over eight to
12 weeks. However, a high level of between-trial statis-
tical heterogeneity is evident. The largest between-group
effect size (3.52 min) was notable for one RCT [19].
Three clinical studies by the same investigator have been
retracted in the past three years. However, excluding this
RCT from the analysis did not significantly alter the
Figure 5 Tramadol different doses - forest plot of IELT outcomes.
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heterogeneity (I-squared = 71%).
The placebo-controlled RCTs prescribed tramadol
doses from 25 mg to 89 mg. Reporting of the methodo-
logical quality across these RCTs was limited. Blinded
outcome assessment was not reported by any of the
RCTs, which may have contributed to detection bias.
Allocation concealment was not reported by five of
RCTs, which may have contributed to selection bias
[16-18,20-22]. One of the RCTs randomised participants
according to their presentation sequence at clinic, which
may have also contributed to selection bias [17]. As
such, these results should be interpreted with caution.
The evidence from one RCT (70 participants) suggests
that there is no difference in IELT between tramadol taken
two to three hours prior to sexual intercourse and paroxe-
tine daily [15]. Conversely, evidence from another RCT
(59 participants) indicates that tramadol is significantly
more effective than paroxetine taken on-demand at in-
creasing IELT [16]. However, concealment of allocation
and blinded outcome assessment were not reported by ei-
ther RCT, and treatment duration was relatively short (six
and four weeks respectively). As such, these results should
be interpreted with caution. One of these RCTs also did
not include a placebo group comparison [15]. Commonly
used SSRIs in the management of PE including paroxetine
(20 to 40 mg/d), are prescribed daily [9]. SSRIs such as
paroxetine are absorbed slowly [24]. The half-lives of flu-
oxetine, paroxetine and sertraline range from 16 to
96 hours [25]. The pharmacokinetic properties of paroxe-
tine may also account for the diverse results for the effects
of tramadol compared with paroxetine on IELT.
Single RCT evidence also suggests that tramadol is sig-
nificantly more effective than sildenafil, lidocaine gel, orbehavioural therapy on IELT in men with PE. However,
reporting of the methodological quality is limited in
terms of concealment of group allocation and blinding
of the outcome assessment across all RCTs included by
this review.
Various assessment methods in terms of ejaculation
control, patient/partners sexual satisfaction, anxiety and
other patient-reported outcomes have been used across
RCTs to measure the effectiveness of tramadol. Across
placebo-controlled RCTs, tramadol was reported as
significantly more effective than placebo for various
patient-reported outcomes. Pooled evidence across trials
(817 participants) suggests that tramadol is associated
with significantly more adverse events including: erectile
dysfunction, constipation, nausea, headache, somno-
lence, dry mouth, dizziness, pruritus (itching), and vo-
miting, than placebo or behavioural therapy over eight
to 12 weeks of treatment. Addiction to tramadol by pa-
tients treated with tramadol for PE was not assessed in
the current evidence base. Likewise, patient acceptability
of treatment was not reported. However, one RCT re-
ported 100% follow-up of all patients prescribed 25 mg,
50 mg or 100 mg of tramadol over 24 weeks [20]. All
participants at all doses (100%) reported somnolence.
The trial was considered of unclear methodological
quality.
With the exception of one RCT [18], all of the in-
cluded RCTs were conduction in non-EU countries, five
being conducted in Middle East and Arab State coun-
tries [15-17,19,20]. In a population-based stopwatch
study, Waldinger et al. [26] observed the largest diffe-
rence in IELT observed between Turkey and partici-
pants from the United Kingdom and the United States.
Because characteristics of PE may differ culturally, the
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ralizable across men from EU countries.
The risk of bias assessment indicates the majority of
RCTs of tramadol in the treatment of PE are of unclear
risk of detection bias, mainly due to limited reporting re-
garding blinding of the outcome assessment. Key aspects
of best practice in RCT design to minimise bias include
a robust randomisation method, concealment of treat-
ment group allocation, and, where possible, blinding of
participants and trial personnel, and blinded outcome
assessment; all of which should be clearly stated in the
RCT report [27].
Although our database search strategy was compre-
hensive, the possibility of a publication bias cannot be
discounted. Insufficient numbers of RCT comparisons
were available for any meaningful assessment of funnel
plot symmetry to be undertaken. Nonetheless, although
the RCTs identified for inclusion were of unclear meth-
odological quality, it could be considered unlikely that
any additional unpublished data for the effects of trama-
dol compared with placebo would contribute signifi-
cantly to the overall findings of this review.
The RCTs evaluating tramadol identified for inclusion
evaluated treatments over four to 12 weeks and none re-
ported a long-term follow-up on efficacy and safety out-
comes, including addiction potential. However, more
important is a requirement for clearer evaluations of the
relationship between treatment-related increases in IELT,
ejaculatory control and sexual satisfaction associated
with tramadol. Adverse event data suggest that tramadol
is associated with a number of adverse events, but that
these appear tolerable. However, the long-term use of
tramadol for the treatment of PE in terms of a safety
profile including addiction potential is unclear from the
current evidence base.
The results observed by this review for the effective-
ness of tramadol in treatment of PE are comparable with
other reviews [6-8]. However, where meta-analyses have
previously been undertaken, methodological errors are
evident [7,8]. This review has pooled data across RCTs,
where appropriate, in a meta-analysis using a mean dif-
ference to summarise IELT outcomes and has avoided
double-counting of participants in the analysis.
The European Association of Urology 2014 Guidelines
on male sexual dysfunction recommend that pharmaco-
logical treatment options include ‘on demand’ dapoxe-
tine, daily use of a longer acting selective serotonin
reuptake inhibitor (SSRI) [off-label use], daily use of clo-
mipramine (off-label use), ‘on demand’ topical local an-
aesthetic agents (off-label use) and ‘on demand’ tramadol
(off-label use) [9]. Given that tramadol has been exten-
sively evaluated against placebo for the treatment of PE in
the current evidence base, with limited head-to-head
comparisons between tramadol and other treatments(paroxetine, sildenafil and lidocaine gel), further direct
comparisons between tramadol and other SSRIs includ-
ing dapoxetine, other PDE5 inhibitors, and other top-
ical anaesthetics should now be investigated. Whilst the
observed increases in IELT were statistically significant
in favour of tramadol, it is difficult to quantify how ac-
ceptable and meaningful these changes are for men
with PE, without being able to evaluate the relationship
between IELT, ejaculation control, and sexual satisfac-
tion from the current RCT evidence base for tramadol.
The trade-off between IELT and other effectiveness out-
comes versus adverse effects and addiction potential
should also be further evaluated.Conclusion
Tramadol appears more effective than placebo or behav-
ioural therapy in the treatment of PE. However, these
findings should be interpreted with caution given the
observed levels of between-study heterogeneity and the
methodological quality of the available evidence.Additional file
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